Hcw Biologics, Inc. (HCWB)
NASDAQ:HCWB
Want to see HCWB full AI Analyst Report?
HCWB Stock Chart & Stats
$3.99
-$0.02(-4.12%)
At close: 4:00 PM EST
$3.99
-$0.02(-4.12%)
Day’s Range― - ―
52-Week Range$0.25 - $7.35
Previous CloseN/A
Volume102.01K
Average Volume (3M)24.74M
Market Cap
$9.45M
Enterprise Value$9.48M
Total Cash (Recent Filing)$1.23M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 07, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.61
Shares Outstanding7,161,150
10 Day Avg. Volume1,418,040
30 Day Avg. Volume24,744,832
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.54
P/FCF Ratio-0.15
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.45
Enterprise Value/Ebitda-15.68
Forecast
1Y Price Target
$5.00Price Target Upside25.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$900.00K
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue ReboundVery high gross margins (~97%) combined with a strong TTM revenue rebound to ~$6.6M indicate durable unit economics on recognized revenue. This suggests the company can scale revenue-efficiently from licensing or productized reagents, supporting sustainable contribution margins as programs commercialize.
Reclaimed Cell-therapy Reagent RightsRegaining full rights to HCW9201/HCW9206 gives HCW direct control of commercially-ready reagents for CAR-T and NK-cell supply chains. Ownership enables partnerships, licensing, and capture of manufacturing value, strengthening long-term addressable market exposure in high-growth cell therapy enablement.
Non-dilutive License Payment And China PartnershipA $7M upfront license plus regional partner equity shifts Phase 1 development costs in China to a third party while preserving milestone and royalty upside. This materially reduces near-term cash needs, provides non-dilutive funding, and builds regional commercialization leverage for long-term value capture.
Bears Say
Large Operating Losses And Cash BurnSustained negative operating and free cash flow (~-$11.5M TTM) and large operating losses undermine financial resilience. Persistent cash burn forces repeated capital raises, increasing dilution risk and creating structural dependence on external financing to sustain R&D and clinical timelines over the next several quarters.
Nasdaq Listing Compliance RiskAn active Nasdaq extension tied to specific bid-price and compliance milestones creates sustained listing risk and heightened governance scrutiny. Failure to meet these conditions could trigger rapid delisting, impairing access to public capital and raising long-term financing and credibility challenges for a cash-burning biotech.
Warrant Approvals And Financing OverhangAdjourned shareholder votes and repeated approval cycles for Armistice-related warrants create protracted governance and financing uncertainty. Ongoing vote solicitations, potential dilution upon exercise, and related costs represent structural execution risk that can complicate future financing plans and investor relations.
HCW Biologics News
HCWB FAQ
What was Hcw Biologics, Inc.’s price range in the past 12 months?
Hcw Biologics, Inc. lowest stock price was $0.25 and its highest was $7.35 in the past 12 months.
What is Hcw Biologics, Inc.’s market cap?
Hcw Biologics, Inc.’s market cap is $9.45M.
When is Hcw Biologics, Inc.’s upcoming earnings report date?
Hcw Biologics, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Hcw Biologics, Inc.’s earnings last quarter?
Hcw Biologics, Inc. released its earnings results on May 14, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of N/A by $0.37.
Is Hcw Biologics, Inc. overvalued?
According to Wall Street analysts Hcw Biologics, Inc.’s price is currently Undervalued.
Does Hcw Biologics, Inc. pay dividends?
Hcw Biologics, Inc. does not currently pay dividends.
What is Hcw Biologics, Inc.’s EPS estimate?
Hcw Biologics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Hcw Biologics, Inc. have?
Hcw Biologics, Inc. has 7,161,150 shares outstanding.
What happened to Hcw Biologics, Inc.’s price movement after its last earnings report?
Hcw Biologics, Inc. reported an EPS of $0.37 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 262.018%.
Which hedge fund is a major shareholder of Hcw Biologics, Inc.?
Currently, no hedge funds are holding shares in HCWB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hcw Biologics, Inc.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
HCWB Stock 12 Month Forecast
Average Price Target
$5.00
▲(25.31% Upside)
Technical Analysis
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Xenetic Biosciences
―
Addex Therapeutics
―
Calidi Biotherapeutics
―
Ownership Overview
12.24% Insiders
0.35% Mutual Funds
4.86% Other Institutional Investors
82.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---